GlioblastomaGUAVANCT07052877
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
An observational study of Glioblastoma and Glioblastoma Multiforme (GBM), run by Royal North Shore Hospital at 1 site in Australia.
Trial summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma, Glioblastoma Multiforme (GBM)
- What is being tested?
- PSMA PET/CT scan
- How many people
- 20 participants
- Where
- 1 siteAustralia
- Study dates
- 11 Dec 2025to Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Glioblastoma patients receiving Bevacizumab as part of standard of care.
Who may be able to join
- > 18 year of age
- ECOG 0-2
- Able to provide informed consent for the study
- Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
- Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
- For bevacizumab treatment as per treating physician
- Able to comply with trial requirements
Who cannot join
- No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
- Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
- Does not fulfill PBS requirements for bevacizumab
- Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site, 1 recruiting
- Recruiting
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065
Alexander Yuile, +61 2 94631171, Alexander.Yuile@health.nsw.gov.au
About this study
Official title: Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM)
- Being tested
- PSMA PET/CT scan
- Keywords
- glioblastoma, anti-VEGF, PSMA, bevacizumab, VEGF, glioma, astrocytoma
- Medical subject headings
- Glioblastoma, Glioma, Astrocytoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PSMA PET/CT scanDiagnostic test
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
| Study group | Role | What they receive |
|---|---|---|
| Patients with glioblastoma receiving Bevacizumab as part of their standard of care | Not described Receives: Diagnostic Test: PSMA PET/CT scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
Measured: Prior to first administration of bevacizumab to 6 weeks after.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2025
- Study start11 Dec 2025
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal North Shore Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alexander Yuile, Royal North Shore Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07052877
- Sponsor's protocol ID
- GUAVA
- Acronym
- GUAVA
- Status last verified
- Aug 2026
- First submitted
- 23 Jun 2025
- Last updated
- 13 Aug 2026
- Results posted
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
- ClinicalTrials.gov ID
- NCT07052877
- Acronym / sponsor ID
- GUAVA / GUAVA
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM)
- Keywords
- glioblastoma, anti-VEGF, PSMA, bevacizumab, VEGF, glioma, astrocytoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Royal North Shore HospitalUniversity, hospital or other
- Study start
- 11 Dec 2025 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 7 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with glioblastoma receiving Bevacizumab as part of their standard of care | – | Diagnostic Test: PSMA PET/CT scan |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Glioblastoma patients receiving Bevacizumab as part of standard of care.
Key inclusion criteria (7 listed)
- > 18 year of age
- ECOG 0-2
- Able to provide informed consent for the study
- Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
- Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
Key exclusion criteria (5 listed)
- No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
- Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
- Does not fulfill PBS requirements for bevacizumab
- Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PSMA PET/CT scanPSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab. | Diagnostic test | Patients with glioblastoma receiving Bevacizumab as part of their standard of care |
Primary outcome
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
Time frame: Prior to first administration of bevacizumab to 6 weeks after.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioblastoma and Glioblastoma Multiforme (GBM), run by Royal North Shore Hospital at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexander Yuile (+61 2 94631171, Alexander.Yuile@health.nsw.gov.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration. (time frame: Prior to first administration of bevacizumab to 6 weeks after.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.